Pre- and post-surgical immunotherapy improves outcomes for patients with operable lung cancer
Compared with pre-surgical (neoadjuvant) chemotherapy alone, adding perioperative immunotherapy – given before and after surgery – significantly improved event-free survival (EFS) in patients with resectable early-stage non-small cell lung cancer (NSCLC), according to researchers from The University of Texas MD Anderson Cancer Center.
Results from the Phase III CheckMate 77T study were published today in the New England Journal...
MD Anderson Research Highlights for December 13, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
ASH: Mantle cell lymphoma patients see improved outcomes with oral combination of ibrutinib and venetoclax
ABSTRACT: LBA-2
The targeted therapy combination of ibrutinib and venetoclax significantly improved progression-free survival (PFS)...
ASH: Novel combination therapy significantly reduces spleen volume in patients with myelofibrosis
ABSTRACT: 620
Combining the JAK inhibitor ruxolitinib with the BCL-xL inhibitor navitoclax was twice as effective in reducing enlarged spleens – a major indicator of clinical improvement – compared with standard-of-care ruxolitinib monotherapy for adult patients with intermediate or high-risk myelofibrosis, a rare bone marrow cancer, according to results of the Phase III TRANSFORM-1 trial reported by researchers from The University...
ASH: Targeted oral therapy reduced disease burden and improved symptoms for patients with rare blood disorder
ABSTRACT: 77
The targeted therapy bezuclastinib was safe and rapidly reduced markers of disease burden while also improving symptoms...
ASH: Novel menin inhibitors show promise for patients with advanced acute myeloid leukemias
ABSTRACTS: 57, 58
Two clinical trials led by researchers from The University of Texas MD Anderson Cancer Center demonstrated...
SABCS: Combining ribociclib with hormone therapy improved patient outcomes in early-stage breast cancer
ABSTRACT: GA03-03
Targeted treatment with ribociclib plus hormone therapy provided significant invasive disease-free survival (iDFS...
MD Anderson and Rigel Pharmaceuticals announce strategic alliance to advance olutasidenib in AML and other cancers
The University of Texas MD Anderson Cancer Center and Rigel Pharmaceuticals, Inc. today announced a multi-year strategic development...
SABCS: Studies suggest novel targeted therapies may benefit patients with metastatic HR+/ HER2- breast cancer
ABSTRACTS: RF01-04 and RF01-07
Two studies led by researchers at The University of Texas MD Anderson Cancer Center demonstrated clinical...
MD Anderson Research Highlights: ASH 2023 Special Edition
ABSTRACTS: 162, 309, 322, 364, 741, 774, 856, 983
SAN DIEGO ― The University of Texas MD Anderson Cancer Center’s Research Highlights...
MD Anderson, TACC and the Oden Institute announce funding for the next round of collaborative cancer research projects
The University of Texas MD Anderson Cancer Center, the Oden Institute for Computational Engineering and Sciences and the Texas Advanced...
MD Anderson’s Katy Rezvani, M.D., receives 2023 Honorific Award from the American Society of Hematology
Katy Rezvani, M.D., Ph.D., professor of Stem Cell Transplantation & Cellular Therapy at The University of Texas MD Anderson...
Eating beans improves gut health, regulates immune and inflammatory processes in colorectal cancer survivors
Incorporating navy beans into the diet of colorectal cancer (CRC) survivors has the potential to positively impact both gut and host health...
New combination improves radiation therapy outcomes in patients with locally advanced and borderline resectable pancreatic cancer
First author Cullen Taniguchi, M.D., Ph.D., passed away suddenly before the final publication of this study. A talented physician-scientist...
MD Anderson Research Highlights for November 15, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
Allison Institute hosts inaugural scientific symposium
The James P. Allison Institute™ at The University of Texas MD Anderson Cancer Center hosted its inaugural scientific symposium on Nov. 10...
MD Anderson announces Institute for Data Science in Oncology to advance mission to end cancer
The University of Texas MD Anderson Cancer Center today announced the launch of its Institute for Data Science in Oncology (IDSO), which integrates...
MD Anderson and Jazz Pharmaceuticals announce five-year collaboration to evaluate zanidatamab in HER2-expressing cancers
The University of Texas MD Anderson Cancer Center and Jazz Pharmaceuticals plc today announced a five-year strategic research collaboration...
MD Anderson Research Highlights: SITC 2023 Special Edition
ABSTRACTS: 1534, 777, 1328, 1526, 1330, 545
The University of Texas MD Anderson Cancer Center’s Research...
MD Anderson Research Highlights for October 25, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
Lung cancer outcomes significantly improved with immunotherapy-based treatment given before and after surgery
A regimen of pre-surgical immunotherapy and chemotherapy followed by post-surgical immunotherapy significantly improved event-free survival...
ESMO: Erdafitinib demonstrates improved responses in FGFR-altered advanced urinary tract cancers
ABSTRACTS: 2359O, 2362MO
Targeted treatment with the fibroblast growth factor receptor (FGFR) inhibitor erdafitinib improved responses...
ESMO: PARP inhibitor plus immunotherapy lowers risk of endometrial cancer progression over chemotherapy alone
ABSTRACT: LBA41
Immunotherapy with the anti-PD-L1 monoclonal antibody durvalumab improved progression-free survival (...
mRNA delivered by extracellular vesicles induces immunotherapy response in glioblastoma
A team of researchers at The University of Texas MD Anderson Cancer Center has developed a new method for using extracellular vesicles to...
Lactate-producing bacteria inside tumors promote resistance to radiation therapy
Researchers at The University of Texas MD Anderson Cancer Center have discovered that lactate-producing intratumoral bacteria drives resistance...
MD Anderson Research Highlights: ESMO 2023 Special Edition
ABSTRACTS: LBA71, 1088MO, 95MO, LBA48, 1082O, 1085O, LBA34, 243MO
The University of Texas MD Anderson Cancer Center’s Research Highlights...
MD Anderson hosts 2023 Leading Edge of Cancer Research Symposium
The University of Texas MD Anderson Cancer Center will host its annual Leading Edge of Cancer Research Symposium Nov. 16-17, 2023, featuring...
Jennifer Wargo, M.D., elected to the National Academy of Medicine
Jennifer Wargo, M.D., professor of Surgical Oncology and Genomic Medicine and core member of the James P. Allison...
MD Anderson launches collaborative initiative to reduce breast cancer disparities in Houston area
The University of Texas MD Anderson Cancer Center today announced the launch of Texas Health Equity Alliance for Breast Cancer (THEAL), a...
MD Anderson Research Highlights for October 4, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
Alejandro Aballay, Pharm.D., Ph.D., named Dean of MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences
The University of Texas MD Anderson Cancer Center and The University of Texas Health Science Center at Houston today announced Alejandro Aballay...
MD Anderson Research Highlights: ASTRO 2023 Special Edition
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
MD Anderson Research Highlights for September 21, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
MD Anderson expands breakthrough research campus with groundbreaking of innovative new facility
The University of Texas MD Anderson Cancer Center today broke ground on a 600,000-square-foot facility intended to anchor the institution’...
Exercise boosts anti-cancer immunity and reduces inflammation in Lynch Syndrome patients
Regular and intense aerobic exercise may reduce the risk of colorectal cancer in patients with Lynch Syndrome (LS) by improving the immune...
Research identifies new potential hurdle for nano-based therapies
Researchers at The University of Texas MD Anderson Cancer Center have discovered that certain nano-based cancer therapies may be less effective...
Intensity-modulated radiation therapy provides long-term benefits to patients with locally advanced lung cancer
Intensity-modulated radiation therapy (IMRT) should be the preferred choice when treating patients with locally advanced non-small cell lung...
Enhanced recovery program successfully reduced opioid use after pancreatic cancer surgery
By improving hospital care pathways, researchers from The University of Texas MD Anderson Cancer Center successfully reduced inpatient opioid...
MD Anderson and Panacea launch Manaolana Oncology to develop antibody-based therapies for cancer
The University of Texas MD Anderson Cancer Center and Panacea Venture today announced the launch of Manaolana Oncology Inc., a new company...
MD Anderson Research Highlights for August 30, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
Combining immunotherapy with KRAS inhibitor eliminates advanced KRAS-mutant pancreatic cancer in preclinical models
Researchers at The University of Texas MD Anderson Cancer Center have uncovered a functional role for KRAS mutations in pancreatic cancer...
MD Anderson receives nearly $4.9 million in CPRIT funding for cancer prevention programs and recruitment
The University of Texas MD Anderson Cancer Center was awarded four grants totaling nearly $4.9 million from the Cancer Prevention and Research...
MD Anderson Research Highlights for August 16, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
University of Texas System Regents announce plans to build UT Medical Center on site of Erwin Center
Today The University of Texas System Board of Regents Chairman Kevin P. Eltife announced plans to launch a monumental healthcare initiative...
MD Anderson names Christopher Flowers, M.D., Division Head of Cancer Medicine
The University of Texas MD Anderson Cancer Center today announced that Christopher Flowers, M.D., an internationally recognized physician-scientist...
MD Anderson Research Highlights for August 2, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
MD Anderson ranked #1 in the nation for cancer care
The University of Texas MD Anderson Cancer Center today was named number one in the nation for cancer care in U.S. News & World Report...
Lost metabolic fitness of CAR NK cells is key mechanism of tumor resistance
A new study led by researchers at The University of Texas MD Anderson Cancer Center discovered loss of metabolic fitness in chimeric antigen...
MD Anderson announces new initiatives in Mozambique and Brazil to advance cancer prevention, treatment, research and education efforts
The University of Texas MD Anderson Cancer Center today announced the expansion of its global oncology efforts in Mozambique and Brazil, including...
MD Anderson and Nexo Therapeutics announce strategic research collaboration to advance new therapies against intractable targets
The University of Texas MD Anderson Cancer Center and Nexo Therapeutics today announced a multi-year strategic collaboration that aligns...
MD Anderson and Replay announce FDA clearance of IND application for first-in-class TCR NK cell therapy for multiple myeloma
The University of Texas MD Anderson Cancer Center and Replay today announced that the Food & Drug Administration (FDA) has issued a ‘safe...
MD Anderson Research Highlights for July 19, 2023
HOUSTON ― The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research...
New single-cell study provides novel insights into gastric cancer
A new study led by researchers at The University of Texas MD Anderson Cancer Center provides a deeper understanding of the evolution of the...
Blood test aids in predicting lung cancer mortality risk
A blood-based test developed by researchers at The University of Texas MD Anderson Cancer Center can predict an individual’s risk of dying...
Largest-ever atlas of normal breast cells brings unprecedented insights into mammary biology
A new study led by researchers at The University of Texas MD Anderson Cancer, University of California, Irvine and Baylor College of Medicine...
MD Anderson Research Highlights for June 27, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
New understanding of why kidney cancers become metastatic discovered by MD Anderson researchers
Researchers at The University of Texas MD Anderson Cancer have engineered a new model of aggressive renal cell carcinoma (RCC), highlighting...
MD Anderson and Ochsner Health announce partnership to create first fully integrated cancer program in Louisiana
The University of Texas MD Anderson Cancer Center and New Orleans-based Ochsner Health today announced a partnership to create Ochsner...
Mutant KRAS regulates Y chromosome gene in colorectal cancer, driving metastasis and inhibiting anti-tumor immunity
Researchers at The University of Texas MD Anderson Cancer Center have uncovered a gene on the Y chromosome that is upregulated in KRAS-mutated...
MD Anderson and Replay announce FDA clearance of IND application for first-in-class TCR NK cell therapy for sarcoma
The University of Texas MD Anderson Cancer Center and Replay today announced that the Food & Drug Administration (FDA) has issued...
Adagrasib effective for patients with KRAS G12C-mutant lung cancer and untreated brain metastases
Researchers from The University of Texas MD Anderson Cancer Center found the KRAS G12C inhibitor adagrasib showed promising activity suppressing...
Study brings new understanding of multiple myeloma evolution
A new study by researchers at The University of Texas MD Anderson Cancer Center highlights novel insights into the evolution of multiple myeloma...
MD Anderson Research Highlights for June 7, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
ASCO: Axi-cel significantly improves survival in patients with early relapsed or refractory large B-cell lymphoma
ABSTRACT: LBA107
CHICAGO – Patients with early relapsed or refractory large B-cell lymphoma had significantly improved overall survival...
ASCO: Targeted therapy achieves responses across multiple cancer types with FGFR alterations
ABSTRACTS: 3121, 4504, LBA4619
Three clinical trials led by researchers at The University of Texas MD Anderson Cancer Center demonstrated...
ASCO: HER2-targeted antibody drug conjugate shows strong anti-tumor activity and durable responses across multiple tumor types
ABSTRACT: LBA3000
In a new study of trastuzumab deruxtecan, a HER2-targeted antibody drug conjugate, researchers observed encouraging...
ASCO: Targeted therapy induces responses in HER2-amplified biliary tract cancer
ABSTRACT: 4008
HER2-targeted bispecific antibody zanidatamab demonstrated durable responses in patients with treatment-refractory HER2...
Pan-cancer T cell atlas reveals new details of tumor microenvironment
A new study led by researchers at The University of Texas MD Anderson Cancer Center, published today in Nature Medicine, provides a deeper...
MD Anderson Research Highlights: ASCO 2023 Special Edition
ABSTRACTS: 398868, 425082, 6546, 3501, 6008, 9502, 9011, 9008
CHICAGO ― The University of Texas MD Anderson Cancer Center’s Research...
ASCO: Luspatercept enables majority of patients with MDS to end reliance on blood transfusions
ABSTRACT: 7003
Treatment with luspatercept improved red blood cell counts and erythroid responses compared to treatment with epoetin...
MD Anderson Research Highlights for May 24, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
MD Anderson awarded over $5.7 million from Break Through Cancer to support AML research
The University of Texas MD Anderson Cancer Center was awarded more than $5.7 million in grants from Break Through Cancer to support collaborative...
Combined delivery of engineered virus with immunotherapy is safe and improves outcomes in subset of patients with glioblastoma
Intratumoral delivery of an engineered oncolytic virus (DNX-2401) targeting glioblastoma (GBM) cells combined with subsequent immunotherapy...
MD Anderson Research Highlights for May 10, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
Allison Institute announces appointment of inaugural members
The James P. Allison Institute™ at The University of Texas MD Anderson Cancer Center today announced the appointment of its first members...
MD Anderson researchers Helen Piwnica-Worms and Richard Wood elected to National Academy of Sciences
Two researchers from The University of Texas MD Anderson Cancer Center have been elected to the prestigious National Academy of...
MD Anderson and Generate:Biomedicines enter co-development and commercialization agreement to accelerate novel protein therapeutics for oncology using generative AI
The University of Texas MD Anderson Cancer Center and Generate:Biomedicines today announced a strategic collaboration to jointly discover...
MD Anderson’s Hagop Kantarjian, M.D., awarded highest honor from American Society of Clinical Oncology
The American Society of Clinical Oncology (ASCO) will present the 2023 David A. Karnofsky Memorial Award to Hagop Kantarjian, M.D...
MD Anderson Research Highlights for April 19, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
AACR: Single-cell study uncovers distinct immunosuppressive tumor microenvironment in brain metastases from kidney cancer
ABSTRACT: 5788
In a new study, researchers from The University of Texas MD Anderson Cancer Center created the largest single-cell atlas...
AACR: Early trial results show benefits of FGFR inhibitors and PARP/ATR inhibitor combinations in multiple tumor types
ABSTRACTS: CT016, CT018
Researchers from The University of Texas MD Anderson Cancer Center presented promising findings...
AACR: Mutations in three key genes associated with poor outcomes in lung cancer patients treated with KRAS G12C inhibitors
ABSTRACT: 3431
A new study led by researchers at The University of Texas MD Anderson Cancer Center discovered that co-occurring mutations...
AACR: Novel allogeneic CAR T cell therapy delivers promising early results in patients with metastatic clear cell renal cell carcinoma
ABSTRACT: CT011
The CD70-targeting allogeneic chimeric antigen receptor (CAR) T cell therapy, ALLO-316, demonstrated encouraging response...
AACR: YAP/TEAD inhibitor VT3989 is well tolerated and shows antitumor activity in advanced mesothelioma and NF2-mutant cancers
ABSTRACT: CT006
The first-in-class YAP/TEAD inhibitor VT3989 was well tolerated with durable antitumor responses in patients with advanced...
MD Anderson Research Highlights AACR 2023 Special Edition
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
Andy Futreal and Helen Piwnica-Worms elected Fellows of the AACR Academy
Two researchers from The University of Texas MD Anderson Cancer Center have been elected to the 2023 class of Fellows of the American Association...
MD Anderson applauds NCI’s National Cancer Plan
The University of Texas MD Anderson Cancer Center applauds the National Cancer Institute’s (NCI) National Cancer Plan and its framework...
Novel immunotherapy delivery approach safe and beneficial for some melanoma patients with leptomeningeal disease
A novel approach to administer intrathecal (IT) immunotherapy (directly into the spinal fluid) and intravenous (IV) immunotherapy was safe...
MD Anderson Research Highlights for March 29, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
Florencia McAllister receives TAMEST Mary Beth Maddox Award for pancreatic tumor microbiome research
Florencia McAllister, M.D., associate professor of Clinical Cancer Prevention, Gastrointestinal Medical Oncology and Immunology at The University...
Dual immunotherapy plus chemotherapy before surgery improves patient outcomes in operable lung cancer
In a Phase II trial led by researchers from The University of Texas MD Anderson Cancer Center, adding ipilimumab to a neoadjuvant, or pre-surgical...
Kerin Adelson, M.D., named MD Anderson Chief Quality and Value Officer
The University of Texas MD Anderson Cancer Center today announced Kerin Adelson, M.D., as the institution’s chief quality and value officer...
MD Anderson Research Highlights for March 8, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
MD Anderson Research Highlights for February 22, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
MD Anderson receives nearly $19.4 million in CPRIT funding
The University of Texas MD Anderson Cancer Center today was awarded 15 grants totaling $19.38 million from the Cancer Prevention and Research...
MD Anderson and Xilis announce strategic collaboration to advance novel technology and accelerate therapeutic development
The University of Texas MD Anderson Cancer Center and Xilis today announced a strategic collaboration to deploy Xilis’ proprietary MicroOrganoSphere...
MD Anderson and KKR-backed Replay form new product company Syena to pioneer first-in-class TCR NK cell therapy
The University of Texas MD Anderson Cancer Center and Replay today announced the launch of Syena, a new oncology-focused product company...
Lung cancer study finds new target for treatment resistance after EGFR inhibitors
Researchers at The University of Texas MD Anderson Cancer Center have identified CD70 as being highly expressed on drug-resistant cancer cells...
Lung cancer screening more cost effective when using risk model-based strategies
Risk model-based lung cancer screening strategies, which select individuals based on personal risk, are more cost effective than current recommendations...
New cell death mechanism could offer novel cancer treatment strategies
A study from researchers at The University of Texas MD Anderson Cancer Center, published today in Nature Cell Biology, details a previously...
MD Anderson announces new collaboration in Indonesia to reduce global cancer burden
The University of Texas MD Anderson Cancer Center today announced the expansion of its global oncology efforts through a new agreement with...
MD Anderson Research Highlights for February 1, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
MD Anderson and Federation Bio announce collaboration to develop novel microbiome treatment for patients with immunotherapy-resistant cancers
The University of Texas MD Anderson Cancer Center and Federation Bio today announced a strategic collaboration to design and manufacture a...
Three MD Anderson researchers elected AAAS Fellows
Three researchers at The University of Texas MD Anderson Cancer Center have been named fellows of the American Association for the Advancement...
Targeted therapy momelotinib provides significant symptom and anemia improvements in patients with myelofibrosis
Patients with myelofibrosis had clinically significant improvement in disease-related symptoms, including anemia and spleen enlargement, when...
MD Anderson EGFR Classification licensed by BostonGene and Tempus to provide new insight on atypical mutations in lung cancer
The University of Texas MD Anderson Cancer Center today announced licensing agreements with BostonGene Corporation and Tempus for the MD Anderson...
MD Anderson’s Jennifer Wargo receives TAMEST O’Donnell Award for pioneering microbiome research
Jennifer Wargo, M.D., professor of Surgical Oncology and Genomic Medicine at The University of Texas MD Anderson Cancer Center, has received...
Scientists develop novel mRNA delivery method using extracellular vesicles
A team of researchers led by The University of Texas MD Anderson Cancer Center has developed a novel delivery system for messenger RNA (mRNA...
MD Anderson Research Highlights for January 11, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer...
Novel T cell receptor therapy shows early anti-tumor activity
Afamitresgene autoleucel (afami-cel; formerly ADP-A2M4), an adoptive T cell receptor (TCR) therapy targeting the MAGE-A4 cancer antigen, achieved...